BioSpace News Archive

Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement.

Biomea Fusion, Inc. today announced the dosing of the first patient with type 2 diabetes in the Phase II portion of COVALENT-111, a Phase I/II clinical trial underway in Canada.

Pluri Inc. today announced its participation in three upcoming conferences. Conference: CPHI Frankfurt Date: November 1-3, 2022 Location: Frankfurt, Germany.

Compugen Ltd. announced today that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022, before the U.S. financial markets open.

CytoSorbents Corporation announced today that the National Institute of General Medical Sciences (NIGMS), a division of the U.S. National Institutes of Health, has granted CytoSorbents a Phase I Small Business Innovation Research (SBIR) award valued at $281,835.

ESSA Pharma Inc. today announced that Janssen Research and Development (“Janssen”) is suspending enrollment into the Phase 1 clinical study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer (“mCRPC”) patients as a result of operational recruitment challenges.

Nuvalent, Inc. today announced that it has commenced an underwritten public offering of $200.0 million of its shares of Class A common stock.

Ardelyx, Inc. today announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor for the improvement of hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis.

Isosceles Pharmaceuticals, Inc. has announced the execution of a non-binding letter of intent with a strategic partner for the phase 1 development of the Company’s intravenous product, IPI 201.

Fianostics GmbH in Austria has launched new COVID-19 antibody test kits that include Mitra® devices from Neoteryx, the microsampling brand of Trajan Scientific and Medical.